The pharmacokinetics, toxicity, and clinical relevance of combining 5-aza and sodium phenylbutyrate, a first-generation HDAC inhibitor, was assessed in 34 patients with refractory solid tumors with no curative options, including two BC patients. The gene discussed is HDAC9; the disease is breast cancer.